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MeropenemAbstract Resistance to broad-spectrum beta-lactams, mediated by extended-spectrum beta-
lactamase enzymes (ESBL), is an increasing problem worldwide. The present study was undertaken
to determine the incidence of ESBL-production among the clinical isolates ofPseudomonas aeruginosa
and their susceptibility to selected antimicrobials. A total of one eighty-seven clinical specimens were
tested for the presence of ESBL production using the double-disc synergy test. Of these, 25.13%
(n= 47) isolates of P. aeruginosa were observed as ESBL positive. The maximum number of
ESBL-producing strains were found in sputum (41.67%; n= 24) followed by pus (28.36%;
n= 19), cerebrospinal ﬂuid and other body ﬂuids (21.74%; n= 5), urine (20.45%; n= 9) and blood
(13.79%; n= 4). ESBL producing isolates exhibited co-resistance to an array of antibiotics tested.
Imipenem and meropenem can be suggested as the drugs of choice in our study.
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The worldwide emergence of multi-drug resistant bacterial
strains in hospitals and community continues to be a problemof due scientiﬁc concern, especially infections caused by
Pseudomonas species andPseudomonas aeruginosa in particular.
P. aeruginosa is an opportunistic pathogen with inherent
resistance to many antibiotics and disinfectants including
anti-pseudomonal Penicillins, Ceftazidime, Carbapenems,
Aminoglycosides and Ciproﬂoxacin (Dundar and Otkun, 2010).
P. aeruginosa is physiologically versatile and ﬂourishes as a
saprophyte in multiple environments, including sinks, drains,
respirators, humidiﬁers and disinfectant solutions. Infections
due to P. aeruginosa are seldom encountered in healthy adults;
but in the last two decades, the organism has become increas-
ingly recognized as an aetiological agent in a variety of serious
Table 1 ESBL-producing P. aeruginosa strains isolated from various samples.
S. No Specimen type No. of P. aeruginosa strains(n= 187) ESBL positive P. aeruginosa strains (n; %) (n= 47)
1. Urine 44 09 (20.45%)
2. Blood 29 04 (13.79%)
3. Pus 67 19 (28.36%)
4. Sputum 24 10 (41.67%)
5. Cerebrospinal ﬂuid body ﬂuid and other 23 05 (21.74%)
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impaired immune defenses (Shahid et al., 2003).
Extended-spectrum beta-lactamases (ESBLs) have emerged
as an important cause of resistance in Gram-negative bacteria.
Beta-lactam antibiotics are among the safest and most fre-
quently prescribed antimicrobial agents all over the world in
treating Gram positive and Gram negative infections
(Bradford, 2001). Production of beta-lactamases is the most
common mechanism of bacterial resistance to these antibiotics.
These enzymes are numerous and are plasmid mediated, capa-
ble of hydrolysing and inactivating a wide variety of beta-lac-
tam antibiotics. In addition, ESBL producing organisms
exhibit co-resistance to many other classes of antibiotics result-
ing in the limitation of therapeutic options. For this reason,
ESBL–mediated infections have been increasingly reported
worldwide (Khanfar et al., 2009).
The aim of the present study was to determine the incidence
of ESBL-production among the clinical isolates of P. aerugin-
osa and their susceptibility to antimicrobials.Table 2 Percent resistance to the selected antimicrobial agents
among the ESBL-positive P. aeruginosa isolates (n= 47).
S. No. Antibiotics S R %R
1 Ampicillin 00 47 100.00
2 Aztreonam 11 28 59.57
3 Amikacin 07 40 85.11
4 Cefotaxime 10 37 78.72
5 Ceftazidime 04 43 91.49
6 Cefazolin 13 34 72.34
7 Cefepime 16 31 65.96
8 Cefoperazone 15 32 68.09
9 Ceftriaxone 08 39 82.98
10 Ciproﬂoxacin 12 35 74.47
11 Piperacillin 18 29 61.70
12 Tigecycline 14 33 70.21
13 Gentamicin 02 45 95.74
14 Imipenem 47 00 00.00
15 Meropenem 47 00 00.00
S = Sensitive, R = Resistant.2. Methods
2.1. Bacterial isolates
One hundred eighty-seven isolates of P. aeruginosa were recov-
ered from various clinical specimens. These included 44 iso-
lates from urine, 29 isolates from blood, 67 isolates from
pus, 24 isolates from sputum and 23 isolates from cerebrospi-
nal ﬂuid and other body ﬂuids. All the specimens were quickly
sent to the laboratory to be processed. Standard methods for
isolation and identiﬁcation of these bacteria were used
(Cowan and Steel, 1970).
2.2. Antimicrobial susceptibility testing and ESBL detection
Antimicrobial susceptibility testing of the isolates was per-
formed by the standard disc diffusion method as recommended
by the Clinical and Laboratory Standards Institute (CLSI,
2008). P. aeruginosa ATCC 27853 was used as a control strain.
ESBL production was detected by double disc synergy test as
described by Jarlier et al. (1998). Synergy was determined
between a disc of amoxyclav (20 lg amoxycillin and 10 lg
clavulanic acid) and a 30 lg disc of each third generation ceph-
alosporin test antibiotic placed 15 mm apart on a lawn culture
of the isolate under test on Mueller Hinton agar plates. The
test organism was considered to produce ESBL if the zone size
around the antibiotic disc increased towards the amoxyclav
disc. This increase occurs as the clavulanic acid present in
the amoxyclav disc inactivates the ESBL produced by the test
organism.3. Results
A total of 187 bacterial isolates were analysed from various
clinical specimens. Of these, 25.13% (n= 47) P. aeruginosa
strains were found to be ESBL positive. The highest number
of ESBL-producers were isolated from sputum (41.67%) fol-
lowed by pus (28.36%), cerebrospinal ﬂuid and other body ﬂu-
ids (21.74%), urine (20.45%) and blood (13.79%) (Table 1).
Antibiotic susceptibility tests were performed for ESBL pro-
ducing isolates. Imipenem and meropenem were found to be
the most effective antibiotics against the ESBL-producing P.
aeruginosa isolates. Zero percent resistance was found against
both imipenem and meropenem. Among the third-generation
cephalosporins, the highest resistance was found against ceft-
azidime, which was 91.49% (n= 43). The percent resistance
to selected antimicrobials exclusively among the ESBL-
producing isolates has been shown in Table 2.
4. Discussion
P. aeruginosa is a leading cause of nosocomial infections,
including pneumonia, urinary tract infections, and bacteremia.
The infections can be particularly severe in patients with
impaired immune systems, such as neutropenic or cancer
patients (Pagani et al., 2004). Infections caused by P. aerugin-
osa are difﬁcult to treat as the majority of isolates show vary-
ing degrees of inherent resistance. Acquired resistance is also
reported by the production of plasmid mediated AmpC beta
(beta)-lactamase, ESBL and metallo beta-lactamase enzymes
(Manchanda and Singh, 2008).
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aeruginosa were ESBL producers. The frequency of ESBL pro-
ducing isolates was highest in sputum (41.67%) followed by
pus (28.36%), cerebrospinal ﬂuid and other body ﬂuids
(21.74%), urine (20.45%) and blood (13.79%). This is in har-
mony with the ﬁndings of Aggarwal et al. (2008).
The ESBL producing P. aeruginosa isolates exhibited co-
resistance against most of the antibiotics tested. This is consis-
tent with most of the recent ﬁndings (Bandekar et al., 2011;
Begum et al., 2013). All ESBL producing P. aeruginosa isolates
were sensitive to imipenem and meropenem. This is in har-
mony with the ﬁndings of Okesola and Oni (2012).
The introduction of carbapenems into clinical practice rep-
resented a great advance for the treatment of serious bacterial
infections caused by beta-lactam resistant bacteria. Due to
their broad spectrum of activity and stability to hydrolysis
by most beta lactamases, carbapenems have been the drug of
choice for treatment of infections caused by penicillin or ceph-
alosporin-resistant Gram-negative bacilli especially, ESBL
producing Gram-negative infections (Mendiratta et al., 2005).
5. Conclusion
The present study determines the prevalence of ESBL produc-
ing P. aeruginosa with limited susceptibility to antimicrobials
in hospital environment. In order to combat these problems
proper antibiotic policies should be formulated. Further, it
was observed that all the ESBL-producing isolates were sus-
ceptible to imipenem and meropenem. This brings due relief
as these are the drugs of choice in the treatment of Pseudomo-
nas infection.
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